Every Tenth New European Drug Developed in Finland
The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.
The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.
The FDA granted market authorization for the IUD Skyla, developed by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. The European MedicinesAgency authorized Selincro, a Biotie drug intended for the treatment of alcohol addiction.
Only about 30 new drugs receive marketing authorization in Europe each year, making the Turku turnout even more remarkable.
Further information here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
